Acquired
Novo Nordisk (Ozempic)
David Rosenthal
Which for sure also apply here. Yeah. I think really on three sides. On the R&D and research side, because that is incredibly capital intensive. $2.3 billion a drug. Yeah. Yep. The production side, as we've talked about for much of the episode, and then also here on the go-to-market side. You can't just, you know, waltz into these markets.
0
💬
0
Comments
Log in to comment.
There are no comments yet.